Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2012 on request of the Sponsor.

On 8 October 2009, orphan designation (EU/3/09/678) was granted by the European Commission to Gregory Fryer Associates Ltd, United Kingdom, for (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione for the treatment of soft tissue sarcoma.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione
Disease / condition
Treatment of soft tissue sarcoma
Date of decision
Orphan decision number

Sponsor's contact details

Gregory Fryer Associates Ltd
30 St Thomas Place
Cambridgeshire Business Park
Ely, Cambridgeshire
United Kingdom
Tel. +44 (0)1353 645590
Fax +44 (0)1353 645599

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating